Phase 1 Trial: Simple Dietary Supplement Could Supercharge Cancer-Fighting Immune Cells
/in Clinical Trial, Not PCa related/by MaxNewsletter 7
/in Newsletter/by MaxLAST WEEK TODAY! A summary of what was published on ProstateWarriors.com during the past week HAPPY NEW YEAR! Before we dive into the latest news from prostatewarriors.com I want to wish you all a great 2025! The seventh and final newsletter of 2024 is here, bringing you fresh insights and renewed hope. We also have a podcast if you prefer […]
Phase 1 Trial Recruiting: Bispecific Antibodies JNJ-87189401 and JNJ-78278343
/in Clinical Trial, Metastatic, Phase 1/by MaxTargeting LIG1 with PARP Inhibitors: E New Target Identified Using CRISPR
/in CRISPR, PARPi, Preclinical Research/by MaxNew Nanoparticle Therapy Holds Promise for Prostate Cancer Patients
/in Delivery, Preclinical Research/by MaxRepurposing FDA-Approved Drugs for PIM-1 Kinase Inhibition: A Potential Avenue for Prostate Cancer
/in Drug repurposing, Preclinical Research/by MaxXaluritamig (AMG 509): Promising Updates on a STEAP1-Targeted Therapy for Advanced Prostate Cancer
/in Clinical Trial, Metastatic, Phase 3/by MaxPhase 1 trial: AVA6000 Targeted Chemotherapy for FAP-Positive Tumors (Including Prostate Cancer)
/in Clinical Trial, Metastatic, Phase 1/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 abiraterone abiraterone acetate ADC ADT ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T CD3 clinical trial crispr darolutamide docetaxel drug repurposing drug resistance enzalutamide EZH2 inhibitor HRR immunotherapy mcrpc mHSPC mRNA NEPC neuroendocrine prostate cancer oncolytic virus PARP1 PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data STEAP1 T-cell therapy
Latest Posts
- Phase 3 DASL-HiCaP: Darolutamide Reduces Metastasis Risk in High-Risk Prostate Cancer October 24, 2026
- UPDATE: PROTEUS Substudy Shows Improved Event-Free Survival With Perioperative Apalutamide October 24, 2026
- UPDATE: Bavdegalutamide Shows Stronger Activity in Prostate Cancers With Specific AR Mutations October 23, 2026
- UPDATE: TheraPb Reports 11.2-Month Median rPFS With 212Pb-ADVC001 October 23, 2026